An investment arm of a leading health system has invested in over 30 companies (with 10 successful exits to date) as well as a few healthcare funds. The firm currently manages over $250M AUM. The firm currently invests from its latest fund that closed in 2022, and generally invests in Series A and B rounds. The firm focuses on investing in solutions that can improve patient outcomes, enhance patient experience, and reduce the cost of healthcare. The firm invests primarily in USA-based companies.
The firm invests in therapeutics, medical devices, diagnostics, healthcare IT and technology-enabled delivery solutions. In terms of stage of development, the firm is looking for those that have already received seed funding and companies are expected to demonstrate strong clinical data/validation. In terms of medical devices, the companies should have a working prototype in place. The firm is capable of investing in all classes of medical devices including those requiring 510(k) and PMA regulatory approval. The firm is open to all types of technologies and indications but prefers those that address an area of large unmet need, including chronic disease management, mental & behavioral health, cardiovascular disease, precision medicine, etc. The firm is also interested in technologies that involve advanced applications of AI.
The firm has no specific company or management team requirements. While the firm has led investment rounds and would seek board representation in those instances, the firm generally acts as a syndicate investor alongside likeminded investors.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment